Following the initial impact of the COVID-19 pandemic, the Japanese market for TEO devices will expand at a modest rate, driven by the steady growth of Japan's aging population. However, revenue growth will continue to be hindered by the delayed entry of newer devices from international competitors and downward pricing pressure from biennial reimbursement cuts. Nonetheless, several new products will enter the market and see increasing adoption over the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for TEO devices in Japan across a 10-year period.

The TEO device market will be affected by the COVID-19 crisis.

How will the COVID-19 outbreak affect the TEO device market?

How quickly are procedure volumes expected to recover?

The Japanese TEO market is distinctive compared to other global markets due to unique demographic trends, physician preferences, and regulatory factors.

What unique regulatory factors impact TEO device approval in Japan?

How will reimbursement affect different TEO device segments during the forecast period?

What strategies can companies use to gain market share in this complex market?

How will physician preferences and adoption of new TEO devices shape the market?

The Japanese flow-diverting device market is characterized by innovation, with the recent entrance of Pipeline Flex and the expectedentry of other flow-diverters over the forecast period.

How will the introduction of new intrasaccular flow-diverting devices affect the neurovascular flow-diverting market?

How has the availability of flow-diverters affected the neurovascular embolization coil and neurovascular coiling-assist device markets?

How will the results derived from clinical trials influence surgeon preferences for neurovascular coils or flow-diverting devices?

Radioembolization spheres are expected to be approved in Japan over the forecast period.

How will the introduction of radioembolization spheres impact the embolization particle market?

How will Japanese guidelines related to the treatment of HCC and metastatic CRC affect the use of these products for each indication?

How will the adoption of radioembolization spheres affect the overall Japanese TEO device market?

Table of contents

  • Transcatheter Embolization And Occlusion Devices - Market Insights - Japan

Author(s): Siva Kumar Pulla, MBA (Pharm)

Siva Kumar Pulla is a market expert specializing in aortic repair devices within the Cardiovascular Medtech Insights team at Decision Resources Group. Siva holds a Bachelor's degree in Pharmaceutical Sciences from Jawaharlal Nehru Technological University and an MBA in Pharmaceutical Marketing from the National Institute of Pharmaceutical Education and Research, Hyderabad.